What Happened
- India accounts for approximately 132,000 new cervical cancer cases and 74,000 deaths annually — nearly one-third of global cervical cancer mortality — making it one of the most severe public health burdens in the world for women.
- India accounts for approximately 25% of global cervical cancer deaths, and one in five women worldwide who suffers from the disease is Indian.
- Despite this burden, India lacked a national HPV vaccination programme until February 2026, when Prime Minister Modi launched a nationwide free vaccination drive offering Gardasil-4 to approximately 1.15 crore girls aged 14, available at all government health facilities.
- The delay was partly attributable to a 2010 controversy over a demonstration project in Andhra Pradesh and Gujarat, in which deaths among vaccinated girls were investigated; a government committee subsequently concluded the deaths were most probably unrelated to the vaccine, but the episode triggered prolonged policy hesitancy.
- Scientific evidence firmly establishes that almost all cervical cancer cases are caused by persistent infection with high-risk HPV — primarily types 16 and 18 — and that vaccination reduces the risk of pre-cancerous lesions and cervical cancer by 90–95% when administered before HPV exposure.
Static Topic Bridges
Cervical Cancer: Epidemiology and the India-Specific Burden
Cervical cancer is the fourth most common cancer in women globally, but in India it remains the second most common cancer among women — after breast cancer. The disproportionate Indian burden stems from multiple factors: limited access to regular cervical screening, late-stage diagnosis, lower awareness in rural and semi-urban populations, and high prevalence of risk factors (early marriage, multiple pregnancies, nutritional deficiencies that weaken immune response to HPV). The cancer is both preventable (through HPV vaccination) and treatable when detected early (through screening and ablative treatment).
- India: ~132,000 new cases and ~74,000 deaths per year from cervical cancer
- Global comparison: India accounts for ~25% of global cervical cancer deaths despite having ~18% of global population
- Age distribution: peak incidence in India occurs in women aged 45–49
- Stage at diagnosis in India: majority diagnosed at Stage III or IV (late stage), significantly reducing survival rates
- Five-year survival rate: ~46% in India (vs. 60%+ in high-income countries) — due largely to late detection
- Root cause: nearly all (99.7%) cervical cancer cases are attributable to persistent HPV infection; HPV 16 and 18 cause >80% of India's cases
Connection to this news: The epidemiological data — particularly India's share of global deaths and the late-stage diagnosis pattern — provides the core public health justification for a universal, free, school-based vaccination programme targeting pre-adolescent girls.
HPV Vaccine: Science, Safety, and Policy History in India
HPV vaccines work by inducing antibodies against the virus's outer protein coat (L1 protein), preventing the virus from entering cervical cells. They are prophylactic (preventive), not therapeutic — they must be administered before HPV exposure for maximum efficacy. Three vaccines are globally licensed: Gardasil-4 (quadrivalent, covers HPV 6/11/16/18), Gardasil-9 (nonavalent, covers 9 types), and Cervarix (bivalent, covers HPV 16/18). India also has an indigenously developed vaccine — Cervavac (Serum Institute of India), a bivalent vaccine targeting HPV 16 and 18, approved by India's Central Drugs Standard Control Organisation (CDSCO) in 2022.
- Efficacy: ~93–100% against HPV 16/18-related precancerous lesions when administered at age 9–14 (before sexual debut)
- WHO recommendation: single dose for girls aged 9–14 (based on immunogenicity data showing equal protection); two doses for ages 15+
- India 2026 programme: Gardasil-4, single dose, free at government facilities, targeting 14-year-olds
- 2009–10 controversy: demonstration project deaths in AP and Gujarat were investigated by multiple bodies (ICMR, WHO) and judged unrelated to vaccine; the episode delayed India's national programme by ~15 years
- National Technical Advisory Group on Immunisation (NTAGI): recommended HPV vaccination for inclusion in the national schedule; its endorsement was a key step toward the 2026 launch
- Cervavac: first indigenously developed HPV vaccine; intended to serve as a cost-effective option for India's public programme
Connection to this news: The 2026 national programme launch represents the resolution of over a decade of policy inertia; the scientific consensus on vaccine safety and efficacy was never in doubt — the delay was primarily a governance and political economy issue.
National Cancer Control Framework in India
India's cancer control strategy operates through the National Programme for Non-Communicable Diseases (NP-NCD) and, specifically for cancer, the National Cancer Control Programme (NCCP), later restructured under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). District Cancer Detection Centres (DCDCs) and the Health and Wellness Centres (HWCs) under Ayushman Bharat provide the ground-level infrastructure for cancer screening. Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PM-JAY) covers treatment costs for eligible families, including cancer care.
- NPCDCS: the nodal national programme for cancer screening and control; includes visual inspection with acetic acid (VIA) for cervical cancer screening
- Ayushman Bharat PM-JAY: covers up to ₹5 lakh per family per year for secondary and tertiary care, including cancer treatment at empanelled hospitals
- HWCs (Health and Wellness Centres): over 1.5 lakh HWCs across India intended to provide preventive, promotive, and primary care including cervical cancer screening
- WHO 90-70-90 strategy: 90% vaccinated, 70% screened, 90% treated — India's 2026 vaccination programme addresses only Target 1; Targets 2 and 3 (screening and treatment) remain significantly under-achieved
- Cervical screening gap: estimated that <30% of eligible women in India have ever been screened
Connection to this news: The launch of the HPV vaccination programme is most impactful when paired with improvements in screening coverage (VIA, HPV DNA testing) and treatment access — areas where India's NCD control infrastructure still has significant gaps to address.
Key Facts & Data
- India's annual cervical cancer burden: ~132,000 new cases, ~74,000 deaths
- India's share of global cervical cancer deaths: ~25%
- HPV types responsible for >80% of India's cervical cancer cases: types 16 and 18
- Vaccine efficacy against HPV 16/18-related disease: 93–100% (pre-exposure)
- National programme launch date: February 28, 2026 (Ajmer, Rajasthan)
- Annual national target: ~1.15 crore girls aged 14
- Vaccine used: Gardasil-4 (quadrivalent, single dose for 9–14 year olds)
- Indigenous alternative: Cervavac (Serum Institute of India, CDSCO approved 2022)
- NTAGI: nodal technical body recommending vaccine additions to India's national schedule
- WHO elimination threshold: <4 cervical cancer cases per 100,000 women per year
- Years lost to policy hesitancy after 2010 controversy: approximately 15 years
- Five-year survival rate for cervical cancer in India: ~46%